摘要:
(wherein R1 represents hydroxy or substituted or unsubstituted lower alkoxy; R2 represents an aromatic heterocyclic group or the like; Y represents lower alkyl or the like; and n represents an integer of from 1 to 6) For example, a process for preparing a 1,3-benzodioxole-2-spirocycloalkane derivative represented by the above formula (VII), which comprises adding a base to a mixture containing a compound represented by the above formula (V) and a compound represented by the above formula (VI); and allowing the compound represented by the above formula (V) to react with the compound represented by the above formula (VI), are provided.
摘要翻译:(其中R 1表示羟基或取代或未取代的低级烷氧基; R 2表示芳族杂环基等; Y表示低级烷基等; n表示 1〜6的整数)例如,上述式(VII)所示的1,3-苯并间二氧杂环戊烯-2-螺环烷烃衍生物的制造方法,其特征在于,在含有上述式 (Ⅴ)表示的化合物和上述式(Ⅵ)表示的化合物。 并且使由上式(Ⅴ)表示的化合物与上式(Ⅵ)表示的化合物反应。
摘要:
The present invention provides condensed purine derivatives or pharmacologically acceptable salts thereof exhibiting adenosine A3 acceptor antagonising activity, and having an antiasthmatic action, a bronchodilator action, an antiantiitching action, etc., and represented by the following formula (I): (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R2 represents hydrogen, lower alkyl, alicyclic alkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted aryl, or a substituted or unsubstituted aromatic heterocyclic group; R3 represents hydrogen, lower alkyl, or substituted or unsubstituted aralkyl; X1 and X2 are the same or different and each represents hydrogen, lower alkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted aryl; and n represents an integer of 0 to 3).
摘要翻译:本发明提供具有腺苷A3受体拮抗活性的缩合嘌呤衍生物或其药理学上可接受的盐,并具有抗哮喘作用,支气管扩张剂作用,抗脱除作用等,并由下式(I)表示:(其中R1表示 取代或未取代的芳基或取代或未取代的芳族杂环基; R 2表示氢,低级烷基,脂环族烷基,取代或未取代的芳烷基,取代或未取代的芳基或取代或未取代的芳族杂环基; R 3表示氢,低级烷基或 取代或未取代的芳烷基; X 1和X 2相同或不同,各自表示氢,低级烷基,取代或未取代的芳烷基或取代或未取代的芳基; n表示0〜3的整数。
摘要:
[1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A2A receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A2A receptors (for example, Parkinson's disease or senile dementia): wherein R1 represents substituted or unsubstituted aryl, or the like; R2 represents hydrogen, halogen, lower alkyl, substituted or unsubstituted aryl, or the like; R3 represents hydrogen, halogen, XR10 (wherein X represents O or S; and R10 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic ring, substituted or unsubstituted aralkyl, lower alkyl, or hydroxy lower alkyl), or the like; and Q represents hydrogen or 3,4-dimethoxybenzyl.
摘要翻译:[1,2,4]具有式(I)表示的三唑并[1,5-c]嘧啶衍生物或其药学上可接受的盐,其具有腺苷A2A受体拮抗作用,可用于治疗或预防由 腺苷A2A受体(例如帕金森病或老年性痴呆)的多动症:其中R1表示取代或未取代的芳基等; R 2表示氢,卤素,低级烷基,取代或未取代的芳基等; R3表示氢,卤素,XR10(其中X表示O或S; R10表示取代或未取代的芳基,取代或未取代的芳族杂环,取代或未取代的芳烷基,低级烷基或羟基低级烷基)等; Q表示氢或3,4-二甲氧基苄基。
摘要:
This invention relates to a novel tetracyclic compound represented by formula (I): ##STR1## or its pharmacologically-acceptable salt. The compound of this invention has strong immunosuppressive activity, and is useful as an immunosuppressive agent and as an agent for treating autoimmune disease.
摘要:
The present invention relates to novel tetracyclic compounds represented by formula (I) ##STR1## (wherein each of X.sup.1 and X.sup.2 independently represents hydrogen or lower alkyl; n represents an integer of 1 to 4), or a pharmaceutically acceptable salt thereof, which are useful as immunosuppressive agents.